BioSpace News Archive

REGENXBIO Inc. (Nasdaq: RGNX) today announced initial data from the ongoing Phase II AAVIATE® trial of RGX-314 for the treatment of wet age-related macular degeneration (wet AMD) using in-office suprachoroidal delivery.

Nabriva Therapeutics plc, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced that it has granted a non-statutory stock option to purchase an aggregate of 100,000 ordinary shares of Nabriva Therapeutics as an inducement to Christopher Naftzger, Nabriva’s newly appointed General Counsel.

The global sleep testing services market is expected to witness a significant growth in the market due to the rising occurrences of sleep disorders all around the world.

Ureteroscopy is a procedure in which a telescope-like device is inserted into the bladder and ureter of a person to diagnose and treat problems related to the urinary tract.

The mobile imaging services market is estimated to observe extensive growth on the back of the rising incidence of chronic diseases.

BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, announced that a scientific abstract titled “Phase 2 Safety and Efficacy Study of Intrathecal MSC-NTF cells in Progressive Multiple Sclerosis” will be presented in an oral presentation at the fully digital 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.